Linked Life Data

18228216

Source:http://linkedlifedata.com/resource/pubmed/id/18228216

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-29
pubmed:abstractText
Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1506-9680
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
110-5
pubmed:dateRevised
2011-10-13
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms.
pubmed:affiliation
Department of Haematology, Collegium Medicum, Jagiellonian University, Kraków, Poland. wj2004@wp.pl
pubmed:publicationType
Journal Article, Review, Meta-Analysis